Northern Trust’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.06M Buy
1,003,089
+124,504
+14% +$283K ﹤0.01% 3050
2026
Q2
$1.78M Buy
878,585
+159,785
+22% +$286K ﹤0.01% 3198
2026
Q1
$1.21M Buy
718,800
+396,080
+123% +$703K ﹤0.01% 3246
2025
Q4
$662K Sell
322,720
-51,616
-14% -$82.1K ﹤0.01% 3553
2025
Q3
$606K Sell
374,336
-18,380
-5% -$31.8K ﹤0.01% 3585
2025
Q2
$766K Buy
392,716
+328,705
+514% +$644K ﹤0.01% 3509
2025
Q1
$140K Hold
64,011
– – ﹤0.01% 4036
2024
Q4
$208K Buy
+64,011
New +$160K ﹤0.01% 3978
2023
Q2
– Sell
-4,812
Closed -$19K – 4558
2023
Q1
$19K Hold
4,812
– – ﹤0.01% 4457
2022
Q4
$14.4K Hold
4,812
– – ﹤0.01% 4535
2022
Q3
$26K Hold
4,812
– – ﹤0.01% 4497
2022
Q2
$21K Hold
4,812
– – ﹤0.01% 4616
2022
Q1
$43K Hold
4,812
– – ﹤0.01% 4562
2021
Q4
$42K Buy
4,812
+2,193
+84% +$24.2K ﹤0.01% 4618
2021
Q3
$30K Buy
+2,619
New +$35.4K ﹤0.01% 4590

Other funds holding IKT

Northern Trust's IKT Position: Q3 2026 in Review

Northern Trust increased its Inhibikase Therapeutics (IKT) stake by 14% in Q3 2026, buying an estimated $283K and bringing the position to 1,003,089 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

Northern Trust first reported a position in IKT in Q3 2021 and has held it in 15 quarters since. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Northern Trust held 1,003,089 shares of Inhibikase Therapeutics worth $2.06M as of Q3 2026.
  • Northern Trust bought 124,504 Inhibikase Therapeutics shares in Q3 2026, an estimated $283K.
  • Inhibikase Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #3050 holding.
  • Northern Trust first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.